Optimizing primary chemotherapy in ovarian cancer.
Primary chemotherapy for advanced ovarian cancer includes the administration of a platinum agent (carboplatin or cisplatin) and a taxane (paclitaxel or docetaxel). Most patients (60% to 80%) experience subjective and objective evidence of a favorable response, with prolonged disease-free and overall survival being noted in a substantial subset of this population. Future investigative efforts will focus on the incorporation of new and novel antineoplastic agents into standard treatment, with the important goals of improving biologic activity, enhancing overall quality of life, and extending survival.
Markman
Maurie
M
Department of Hematology/Medical Oncology (R-35), Cleveland Clinic Cancer Center, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA. markmam@ccf.org
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D002986:Clinical Trials as Topic; D018572:Disease-Free Survival; D000077143:Docetaxel; D005260:Female; D006801:Humans; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects
D043823:Taxoids; D000077143:Docetaxel; D016190:Carboplatin; D017239:Paclitaxel; D002945:Cisplatin